Literature DB >> 33436112

The other 'C': Hospital-acquired Clostridioides difficile infection during the coronavirus disease 2019 (COVID-19) pandemic.

Karl Hazel1, Mairead Skally2, Emily Glynn1, Margaret Foley3, Karen Burns2,3, Aoibhlinn O'Toole1, Karen Boland1, Fidelma Fitzpatrick2,3,4.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33436112      PMCID： PMC7870903          DOI： 10.1017/ice.2021.3

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN： 0899-823X            Impact factor:   3.254


× No keyword cloud information.
  10 in total

Review 1.  Empiric Antibiotics in COVID 19: A Narrative Review.

Authors:  Elvina C Lingas
Journal:  Cureus       Date:  2022-06-02

2.  Comparison of trends in Clostridioides difficile infections in hospitalised patients during the first and second waves of the COVID-19 pandemic: A retrospective sentinel surveillance study.

Authors:  Karuna E W Vendrik; Amoe Baktash; Jelle J Goeman; Céline Harmanus; Daan W Notermans; Sabine C de Greeff; Ed J Kuijper
Journal:  Lancet Reg Health Eur       Date:  2022-06-28

Review 3.  Potential Roles for Probiotics in the Treatment of COVID-19 Patients and Prevention of Complications Associated with Increased Antibiotic Use.

Authors:  Ravina Kullar; Stuart Johnson; Lynne V McFarland; Ellie J C Goldstein
Journal:  Antibiotics (Basel)       Date:  2021-04-09

4.  The burden of Clostridioides difficile infection in COVID-19 patients: A systematic review and meta-analysis.

Authors:  Guido Granata; Nicola Petrosillo; Samir Al Moghazi; Emanuela Caraffa; Vincenzo Puro; Glenn Tillotson; Maria Adriana Cataldo
Journal:  Anaerobe       Date:  2021-11-26       Impact factor: 2.837

Review 5.  Bacterial and Fungal Gut Dysbiosis and Clostridium difficile in COVID-19: A Review.

Authors:  Laura Linares-García; María E Cárdenas-Barragán; Winston Hernández-Ceballos; Carlos S Pérez-Solano; Alizon S Morales-Guzmán; Danielle S Miller; Max Schmulson
Journal:  J Clin Gastroenterol       Date:  2022-04-01       Impact factor: 3.062

6.  Impact of COVID19 pandemic on the incidence of health-care associated Clostridioides difficile infection.

Authors:  Nicolás Merchante; Pablo Chico; Esther Márquez-Saavedra; Gerónima Riera; Rocío Herrero; Pilar González-de-la-Aleja; Ana I Aller; Juan Carlos Rodríguez; Miguel Rodríguez-Fernández; José Manuel Ramos; Marta Trigo-Rodríguez; Esperanza Merino
Journal:  Anaerobe       Date:  2022-04-30       Impact factor: 2.837

7.  Clinical Impact of COVID-19 on Multi-Drug-Resistant Gram-Negative Bacilli Bloodstream Infections in an Intensive Care Unit Setting: Two Pandemics Compared.

Authors:  Francesco Cogliati Dezza; Gabriele Arcari; Federica Alessi; Serena Valeri; Ambrogio Curtolo; Federica Sacco; Giancarlo Ceccarelli; Giammarco Raponi; Francesco Alessandri; Claudio Maria Mastroianni; Mario Venditti; Alessandra Oliva
Journal:  Antibiotics (Basel)       Date:  2022-07-09

8.  Clostridioides difficile infection epidemiology and clinical characteristics in COVID-19 pandemic.

Authors:  Silvia Vázquez-Cuesta; María Olmedo; Elena Reigadas; Luis Alcalá; Mercedes Marín; Patricia Muñoz; Emilio Bouza
Journal:  Front Med (Lausanne)       Date:  2022-08-22

9.  Trends in Clostridioides difficile infection rates in Canadian hospitals during the coronavirus disease 2019 (COVID-19) pandemic.

Authors:  Kelly B Choi; Tim Du; Anada Silva; George R Golding; Linda Pelude; Robyn Mitchell; Wallis Rudnick; Romeo Hizon; Ghada N Al-Rawahi; Blanda Chow; Ian Davis; Gerald A Evans; Charles Frenette; Jennie Johnstone; Pamela Kibsey; Kevin C Katz; Joanne M Langley; Bonita E Lee; Yves Longtin; Dominik Mertz; Jessica Minion; Michelle Science; Jocelyn A Srigley; Paula Stagg; Kathryn N Suh; Nisha Thampi; Alice Wong; Jeannette L Comeau; Susy S Hota
Journal:  Infect Control Hosp Epidemiol       Date:  2022-08-18       Impact factor: 6.520

Review 10.  Epidemiology of community-acquired and recurrent Clostridioides difficile infection.

Authors:  Yichun Fu; Yuying Luo; Ari M Grinspan
Journal:  Therap Adv Gastroenterol       Date:  2021-05-22       Impact factor: 4.409
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.